Nektar Therapeutics (NKTR) is in Healthcare, Biotechnology, based in United States, listed on NasdaqCM. Market cap 1.39B USD. 52-week range 33.40 to 109.00 USD. Data as of 2026-10-09.
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat ...